

around the world

since 2012: 21 bone & tissue days in 16 countries

Berlin,
Germany: 05/2012
/ London, UK: 10/2012 /
Bangkok, Thailand: 09/2013 / Budapest,
Hungary: 09/2013 / Madrid, Spain: 09/2013
/ Istanbul, Turkey: 11/2013 / Copenhagen,
Denmark: 05/2014 / Bucharest, Romania: 05/2014
/ Opatija, Croatia: 05/2014 / Cape Town, South
Africa: 06/2014 / Saint Petersburg, Russia: 06/2014 /
Berlin, Germany: 09/2014 / Madrid, Spain: 10/2014
/ Medellín, Colombia: 02/2015 / Baku, Azerbaijan:
04/2015 / Køge, Denmark: 05/2015 / Bucharest,
Romania: 10/2015 / Madrid, Spain: 10/2015
/ Hong Kong, China: 12/2015 / Porto,
Portugal: 11/2015 / Salzburg,
Austria: 12/2015

The bone & tissue days are an innovative congress concept with a strong focus on dental hard and soft tissue regeneration. They are characterized by a combination of theoretical clinical-scientific lectures and practically orientated workshops.

SAVE THE DATE:

Berlin,
8 - 10 September 2016

3rd bone & tissue days / World Congress

**ONLINE REGISTRATION
and more information on the
forthcoming bone & tissue days at**
www.boneandtissue.com

straumann
simply doing more


ITI
International Team
for Implantology

2014 World wide cooperation with Straumann
in the field of regenerative products

2015 botiss participation at
8 ITI congresses world wide

2017/2018 | Scheduled market
launch in USA, Australia, Brazil

Innovation.
Regeneration.
Aesthetics.



Products distributed in
~100
countries world wide

botiss biomaterials GmbH
Hauptstr. 28
15806 Zossen / Berlin
Germany

Tel.: +49 33769 / 88 41 985
Fax: +49 33769 / 88 41 986

contact@botiss.com
www.facebook.com/botissdental

www.indication-matrix.com
www.boneandtissue.com
www.botissacademy.com

www.botiss.com

botiss
biomaterials

INSIDE

2016

ISO 13485
Certified

High Standards /
Medical devices /
Pharmaceutical products /
Pharmaceutical entrepreneur /

botiss biomaterials

botiss biomaterials is an innovative, clinically and scientifically driven, biotech company with head office in Zossen / Berlin. The production sites are located in Krems (AT), Sheffield (UK), Dieburg (DE) and Neustadt-Glewe (DE). Our regeneration products are distributed world wide in about 100 countries.


According to MDD 93/42/EEC botiss is a legal manufacturer of medical devices. Therefore, we have implemented a quality management system conforming to EN ISO 13485.

Pharmaceutical entrepreneur according to Section 4 Subsection 18 of the German Medicines Act (AMG)
Placement of pharmaceutical products on the market

In-House Development / Production / Distribution

Our indication-oriented product portfolio (which includes a range of bone-substitute and collagen biomaterials), our continuous research for innovation and a wide clinical and scientific network, have led botiss biomaterials to become one of the major companies in the dental regeneration field in recent years.

www.indication-matrix.com



30%
out of 100 botiss employees
are scientists.

> 60 ongoing studies carried out in national and international research centers

> 200.000 patients treated world wide in 2015

clinical and scientific collaboration with
~ 50 universities and research institutions around the world

botiss biomaterials acts as a link between developers, researchers, and clinicians, with a key focus on the everyday-practice experience. This is the driving force that leads us to a continuous development of new materials and to the optimization of established products. In addition, our world wide cooperation with prominent research centers and key opinion leaders gives further impulse for pioneering clinical solutions and trends in the field of tissue regeneration.

> 200 clinical and scientific contributions

INNOVATIVE PATIENT-TAILORED PRODUCTS + THERAPEUTIC CONCEPTS

As a future-oriented company, botiss biomaterials invests in cutting-edge research such as in stem cells and growth factors. We are convinced that the investigation of the interaction between biomaterials and stem cells and/or signaling proteins may pave the way for new approaches to develop innovative technologies and products.

Asst. Prof. Stavros Pelekanos
I find myself quite comfortable in the presence of botiss family especially to take part in the worldwide bone & tissue days congresses. It's also quite a big advantage to have an access to such unique portfolio as the one from botiss. Due to the diversity, I can specifically select certain product for each indication individually and therefore maximize the result. Even more important, this strategy has already proven to be really working. Especially the high quality of the products contributes even further.

Dr. Marius Steigmann
Products from botiss are perfectly designed to match one another and to be used in combination for every single clinical situation, from sinus lift to horizontal/vertical augmentations or the improvement of the soft tissue quality.

Prof. Dr. Adrian Kasaj
Courses and congresses organized by botiss always offer a beneficial mix of relevant topics, internationally renowned speakers and a friendly atmosphere with a balanced ratio of science and practice (so, something for everyone). A key aspect of these events is the wide range of workshops, which allows the participants to directly apply the learned concepts.

Prof. Dr. Anton Sculean, M.Sc.
In many cases I use mucoderm® as an alternative for connective tissue graft. Due to its high biocompatibility and excellent mechanical properties mucoderm® is perfectly suitable for the tunneling procedure. Moreover, it serves also as an ideal carrier for biologic active substances such as Emdogain or other growth factors.

botiss biomaterials aims to set new standards and drive innovations. To achieve this, we dedicate particular effort to the organization of high-quality advance-training programs. For instance, the botiss academy offers several course formats in Germany and abroad with a focus on different topics such as implantology, periodontology, and soft tissue regeneration. The success of this approach attracts internationally renowned experts, who then share and discuss their clinical and scientific results.

SCIENCE
CLINIC
EDUCATION

> 30 on-demand Webinars

www.botissacademy.com

2002 CE mark approval for cerabone® Employed since 2006 in the dental field	2007 CE mark approval for maxresorb®	2008 establishment of botiss medical AG	2009	2010 CE mark approval for collprotect® membrane CE mark approval for Jason® membrane	2011 CE mark approval for mucoderm® and for maxresorb® inject Acquisition of Cells-Tissuebank Austria	2012 First bone & tissue days in Berlin	2013 Exclusive cooperation with the Charité tissue bank for the dental regeneration	2014 Pharmaceutical approval for maxgraft® and for maxgraft® bonebuilder Second bone & tissue days in Berlin with 800 participants	2015 Market launch of maxgraft® cortico	2016 Third bone & tissue days in Berlin CE mark approval permamem scheduled
--	--	---	-------------	---	--	---	---	---	---	--

* Coming soon